Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases 2025 Annual Meeting
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease Liver Meeting 2025
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update
Standard Uranium Provides Drilling Update on the 2026 Drill Program at Flagship Davidson River Project - Announces Elevated Radioactivity in First Drill Hole
Goldgroup Closes Purchase of the San Francisco Gold Mine Acquiring 100% of Molimentales Del Noroeste, S.A. de C.V.
Bold Ventures Commences Summer Fieldwork at Burchell, Follows up at 111 Zone and JET Rare Earth Element System
